{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:14:12Z","timestamp":1792815252380,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.cyto.2021.155469","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T11:11:41Z","timestamp":1613560301000},"page":"155469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["H\u039cGB1\/sRAGE levels differ significantly between transudates and exudates"],"prefix":"10.1016","volume":"141","author":[{"given":"Ourania S.","family":"Kotsiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh M.","family":"Jagirdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios D.","family":"Papazoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrissi","family":"Hatzoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos I.","family":"Gourgoulianis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios G.","family":"Zarogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2021.155469_b0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.toxrep.2019.03.002","article-title":"HMGB1 protein as a novel target for cancer","volume":"6","author":"Tripathi","year":"2019","journal-title":"Toxicol. Reports"},{"key":"10.1016\/j.cyto.2021.155469_b0010","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/jcmm.13048","article-title":"Emerging role of HMGB1 in lung diseases: friend or foe","volume":"21","author":"Ding","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.cyto.2021.155469_b0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fimmu.2013.00068","article-title":"HMGB1: The central cytokine for all lymphoid cells","volume":"4","author":"Li","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2021.155469_b0020","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3390\/diagnostics5020219","article-title":"Circulating HMGB1 and RAGE as clinical biomarkers in malignant and autoimmune diseases","volume":"5","author":"Pilzweger","year":"2015","journal-title":"Diagnostics"},{"key":"10.1016\/j.cyto.2021.155469_b0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12948-017-0068-1","article-title":"Association between HMGB1 and asthma: A literature review","volume":"15","author":"Imbalzano","year":"2017","journal-title":"Clin. Mol. Allergy."},{"key":"10.1016\/j.cyto.2021.155469_b0030","doi-asserted-by":"crossref","first-page":"8862","DOI":"10.1002\/jcp.27548","article-title":"Downregulation of HMGB1 is required for the protective role of Nrf2 in EMT-mediated PF","volume":"234","author":"Qu","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.cyto.2021.155469_b0035","article-title":"MicroRNA-200c inhibits epithelial-mesenchymal transition, invasion, and migration of lung cancer by targeting HMGB1","volume":"12","author":"Liu","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cyto.2021.155469_b0040","doi-asserted-by":"crossref","first-page":"20507","DOI":"10.18632\/oncotarget.7050","article-title":"The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer","volume":"7","author":"Feng","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.cyto.2021.155469_b0045","first-page":"1","article-title":"Pathway-based gene signatures predicting clinical outcome of lung adenocarcinoma","volume":"5","author":"Chang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2021.155469_b0050","doi-asserted-by":"crossref","first-page":"32706","DOI":"10.18632\/oncotarget.16188","article-title":"High mobility group box 1 antagonist limits metastatic seeding in the lungs via reduction of cell-cell adhesion","volume":"8","author":"Karsch-Bluman","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.cyto.2021.155469_b0055","doi-asserted-by":"crossref","first-page":"5756102","DOI":"10.1155\/2017\/5756102","article-title":"Serum HMGB1 as a potential biomarker for patients with asbestos-related diseases","volume":"2017","author":"Ying","year":"2017","journal-title":"Dis. Markers"},{"key":"10.1016\/j.cyto.2021.155469_b0060","doi-asserted-by":"crossref","unstructured":"I. Ugrinova, E. Pasheva, HMGB1 Protein: A therapeutic target inside and outside the cell, in: Adv. Protein Chem. Struct. Biol., Academic Press Inc., 2017: pp. 37\u201376. https:\/\/doi.org\/10.1016\/bs.apcsb.2016.10.001.","DOI":"10.1016\/bs.apcsb.2016.10.001"},{"key":"10.1016\/j.cyto.2021.155469_b0065","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.semcancer.2017.07.001","article-title":"Moinuddin, AGEs, RAGEs and s-RAGE; friend or foe for cancer","volume":"49","author":"Ahmad","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.cyto.2021.155469_b0070","first-page":"1","article-title":"High mobility group box 1-induced epithelial mesenchymal transition in human airway epithelial cells","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2021.155469_b0075","doi-asserted-by":"crossref","first-page":"50417","DOI":"10.18632\/oncotarget.10413","article-title":"HMGB1 overexpression as a prognostic factor for survival in cancer: A meta-analysis and systematic review","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.cyto.2021.155469_b0080","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.ajpath.2013.07.029","article-title":"Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-\u03b1 signaling","volume":"183","author":"Qi","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cyto.2021.155469_b0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1471-2407-13-205","article-title":"Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma","volume":"13","author":"Tabata","year":"2013","journal-title":"BMC Cancer."},{"key":"10.1016\/j.cyto.2021.155469_b0090","doi-asserted-by":"crossref","first-page":"12611","DOI":"10.1073\/pnas.1006542107","article-title":"Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation","volume":"107","author":"Yang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cyto.2021.155469_b0095","doi-asserted-by":"crossref","unstructured":"R.W. Light, M.I. Macgregor, P.C. Luchsinger, W.C.Jr. Ball, Pleural effusions: the diagnostic separation of transudates and exudates, Ann Intern Med. 77 (1972) 507\u2013513.","DOI":"10.7326\/0003-4819-77-4-507"},{"key":"10.1016\/j.cyto.2021.155469_b0100","first-page":"5013","article-title":"Elevated levels of HMGB1 in cancerous and inflammatory effusions","volume":"29","author":"Winter","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.cyto.2021.155469_b0105","doi-asserted-by":"crossref","first-page":"338","DOI":"10.5301\/tj.5000656","article-title":"Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells","volume":"104","author":"Ma","year":"2018","journal-title":"Tumori."},{"key":"10.1016\/j.cyto.2021.155469_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.resp.2019.103330","article-title":"Expression of IL-1\u03b2, HMGB1, HO-1, and LDH in malignant and non-malignant pleural effusions","volume":"272","author":"Wu","year":"2020","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.cyto.2021.155469_b0115","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.21037\/jtd.2016.05.94","article-title":"The diagnostic utility and tendency of the soluble receptor for advanced glycation end products (sRAGE) in exudative pleural effusion","volume":"8","author":"Sim","year":"2016","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.cyto.2021.155469_b0120","doi-asserted-by":"crossref","DOI":"10.1007\/s10753-019-01070-6","article-title":"Pleural effusion IL-33\/sST2 levels and effects of low and high IL-33\/sST2 levels on human mesothelial cell adhesion and migration","author":"Kotsiou","year":"2019","journal-title":"Inflammation"},{"key":"10.1016\/j.cyto.2021.155469_b0125","first-page":"2693","article-title":"Non-oxidizable HMGB1 induces cardiac fibroblasts migration via CXCR4 in a CXCL12-independent manner and worsens tissue remodeling after myocardial infarction","volume":"2017","author":"Di Maggio","year":"1863","journal-title":"Biochim. Biophys. Acta - Mol. Basis Dis."},{"key":"10.1016\/j.cyto.2021.155469_b0130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40520-015-0402-8","article-title":"Decreased serum level of HMGB1 and MyD88 during human aging progress in healthy individuals","volume":"28","author":"Fu","year":"2016","journal-title":"Aging Clin. Exp. Res."},{"key":"10.1016\/j.cyto.2021.155469_b0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12979-017-0095-2","article-title":"Age dependent accumulation patterns of advanced glycation end product receptor (RAGE) ligands and binding intensities between RAGE and its ligands differ in the liver, kidney, and skeletal muscle","volume":"14","author":"Son","year":"2017","journal-title":"Immun. Ageing."},{"key":"10.1016\/j.cyto.2021.155469_b0140","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000076770","article-title":"Age-dependent expression of advanced glycation end product receptor genes in the human heart","volume":"50","author":"Casselmann","year":"2004","journal-title":"Gerontology"},{"key":"10.1016\/j.cyto.2021.155469_b0145","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0006-8993(02)04149-5","article-title":"RAGE is expressed in pyramidal cells of the hippocampus following moderate hypoxic-ischemic brain injury in rats","volume":"966","author":"Ma","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.cyto.2021.155469_b0150","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1179\/1351000215Y.0000000023","article-title":"Pleural effusion levels of dj-1 are increased in elderly lung cancer patients with malignant pleural effusions","volume":"20","author":"Vavougios","year":"2015","journal-title":"Redox Rep."},{"key":"10.1016\/j.cyto.2021.155469_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinbiochem.2012.11.024","article-title":"Pleural fluid protein is inversely correlated with age in uncomplicated parapneumonic pleural effusions","volume":"46","author":"Zarogiannis","year":"2013","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.cyto.2021.155469_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086903","article-title":"The receptor for advanced glycation end-products (RAGE) is only present in mammals, and belongs to a family of cell adhesion molecules (CAMs)","volume":"9","author":"Sessa","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cyto.2021.155469_b0165","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150239","article-title":"RhHMGB1 drives osteoblast migration in a TLR2\/TLR4- and NF-\u03baB-dependent manner","volume":"36","author":"Li","year":"2016","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.cyto.2021.155469_b0170","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1074\/jbc.M112.434142","article-title":"High mobility group box 1 inhibits human pulmonary artery endothelial cell migration via a toll-like receptor 4- and interferon response factor 3-dependent mechanism(s)","volume":"288","author":"Bauer","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cyto.2021.155469_b0175","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9440(10)62344-9","article-title":"Angiogenetic signaling through hypoxia HMGB1: An angiogenetic switch molecule","volume":"166","author":"Schlueter","year":"2005","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cyto.2021.155469_b0180","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1152\/physrev.00037.2018","article-title":"Passing the vascular barrier: Endothelial signaling processes controlling extravasation","volume":"99","author":"Wettschureck","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.cyto.2021.155469_b0185","doi-asserted-by":"crossref","first-page":"15034","DOI":"10.18632\/oncotarget.14746","article-title":"Targeted breast cancer therapy by harnessing the inherent blood group antigen immune system","volume":"8","author":"Han","year":"2017","journal-title":"Oncotarget."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466621000491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466621000491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:00:00Z","timestamp":1760907600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466621000491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":37,"alternative-id":["S1043466621000491"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2021.155469","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"H\u039cGB1\/sRAGE levels differ significantly between transudates and exudates","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2021.155469","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155469"}}